XTX301, a Tumor-Activated Interleukin-12 Has the Potential to Widen the Therapeutic Index of IL12 Treatment for Solid Tumors as Evidenced by Preclinical Studies.

导出 OA

翻译打印收藏纠错

作者： Ekta,Patel ^[1] ; Natalia V,Malkova ^[1] ; David,Crowe ^[1] ; Magali,Pederzoli-Ribeil ^[1] ; Damiano,Fantini ^[1] ; Manoussa,Fanny ^[1] ; Hanumantha Rao,Madala ^[1] ; Kurt A,Jenkins ^[1] ; Oleg,Yerov ^[1] ; Justin,Greene ^[1] ; Wilson,Guzman ^[1] ; Caitlin,O'Toole ^[1] ; Jacob,Taylor ^[1] ; Rebekah K,O'Donnell ^[2] ; Parker,Johnson ^[1] ; Bernard B,Lanter ^[1] ; Brian,Ames ^[3] ; Jia,Chen ^[4] ; Sallyann,Vu ^[1] ; Hsin-Jung,Wu ^[5] ; Susan,Cantin ^[6] ; Megan,McLaughlin ^[1] ; Yu-Shan S,Hsiao ^[1] ; Dheeraj S,Tomar ^[7] ; Raphael,Rozenfeld ^[8] ; Lakshmanan,Thiruneelakantapillai ^[9] ; Ronan C,O'Hagan ^[10] ; Benjamin,Nicholson ^[1] ; Jennifer,O'Neil ^[1] ; Carl Uli,Bialucha ^[1]

作者单位： Xilio Therapeutics, Inc., Waltham, Massachusetts. ^[1] Independent Researcher, Boston, Massachusetts. ^[2] Werfen Therapeutics, Bedford, Massachusetts. ^[3] Alnylam Pharmaceuticals, Cambridge, Massachusetts. ^[4] Tango Therapeutics, Bedford, Massachusetts. ^[5] Jnana Therapeutics, Boston, Massachusetts. ^[6] Kisbee Therapeutics, Cambridge, Massachusetts. ^[7] Wrench Bio, Watertown, Massachusetts. ^[8] Orna Therapeutics, Watertown, Massachusetts. ^[9] Apricity Health, Houston, Texas. ^[10]